Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer
| Autor: | Han Xu, Hanqing Liu, Ruyan Li, Lu Ziwen, Zhiquan Liang, Lanlan Liu, Mengchen Ji, Yuhua Yang, Yibang Zhang, Mingxiang Shen, Dewan Ren, Peng Liu, Zhigang Tu, Dongsheng Shang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Cancer Research Combination therapy Poly ADP ribose polymerase Antineoplastic Agents Synthetic lethality Poly(ADP-ribose) Polymerase Inhibitors Poly (ADP-Ribose) Polymerase Inhibitor Small Molecule Libraries 03 medical and health sciences 0302 clinical medicine Humans Medicine Cytotoxic T cell Pharmacology (medical) Polymerase Ovarian Neoplasms Pharmacology biology business.industry medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer cell Cancer research biology.protein Drug Therapy Combination Female business Ovarian cancer |
| Zdroj: | Anti-Cancer Drugs. 30:554-561 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/cad.0000000000000793 |
| Popis: | Ovarian cancer is a heterogeneous disease with complex molecular and genetic hallmarks. Benefitting from profound understanding of molecular mechanisms in ovarian cancer pathogenesis, novel targeted drugs have been actively explored in preclinical studies and clinical trials. Considered as one of the most potent and effective targeted therapies for the treatment of ovarian cancer, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) take advantages of synthetic lethality mechanisms to prevent DNA damage repair in cancer cells and cause their death, especially in cancers with BRCA mutations. Mounting evidence has indicated that the combination of PARPis with cytotoxic drugs or other targeted drugs has shown favorable synergistic effects. Excitingly, the antitumor activity of combination therapy of PARPis has been actively tested in multiple clinical trials and in-vitro or in-vivo experiments. In this review, we will briefly discuss the molecular mechanisms of PARPis combined with other therapeutic small-molecular compounds for the treatment of ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|